步長製藥(603858.SH):擬放棄優先受讓控股子公司股權
格隆匯7月8日丨步長製藥(603858.SH)公佈,公司控股子公司步長臻澤股東張建蒼擬將其未實繳的步長臻澤0.50%股權轉讓給張雨博、馬曉騰擬將其未實繳的步長臻澤1.00%股權轉讓給李德義,上述股權轉讓價格均爲0元。公司同意放棄上述股權轉讓的優先受讓權。本次轉讓完成後,公司持有步長臻澤90.00%股權比例不變。
公司控股子公司步長冠優股東劉安安擬將其未實繳的步長冠優2.00%股權轉讓給何濤,於海銘擬將其未實繳的步長冠優2.00%股權中的1.00%股權轉讓給羅文清,另外1.00%股權轉讓給魏齊文,上述股權轉讓價格均爲0元。公司同意放棄上述股權轉讓的優先受讓權。本次轉讓完成後,公司持有步長冠優90.00%股權比例不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.